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Aim: To investigate the effects of short-acting analogue insulins on weight, and to demonstrate the difference between analogues.
Materials and methods: Our study included patients who have used only intensive insulin therapy with metformin. Those who took
other oral antidiabetics, other insulin derivatives, or different insulin combinations were excluded from the study because of the adverse
effects on patients’ weights.
Results: Our study included 118 patients who used insulin glargine with short-acting analogue insulins, i.e. insulin aspart (38 patients),
insulin lispro (28 patients), and insulin glulisine (52 patients). After 3 to 6 months of treatment, significant weight gain was observed
in the patients who had used insulin aspart and insulin glulisine (P = 0.008). However, in contrast to expectations, it was found that
patients who had used insulin lispro experienced weight loss. Weight change in the patient group that used insulin lispro compared with
weight change in the insulin glulisine group was found to be statistically significant (P = 0.034).
Conclusion: Our study showed that patients who used short-acting insulin analogues gained a little weight, patients who used insulin
glulisine gained the most weight, and patients who used insulin lispro lost weight.
Key words: Type 2 diabetes mellitus, weight gain, insulin aspart, insulin lispro, insulin glulisine

1. Introduction
Diabetes mellitus, associated with defective insulin
secretion and/or the effect of insulin, is a metabolic
disease characterized by chronic hyperglycemia that
results in a carbohydrate metabolism disorder. Chronic
hyperglycemia may cause failure and dysfunction of
various organs such as the eyes, kidneys, nerves, heart,
and blood vessels (1). Insulin supplementation is the most
effective agent for prevention of chronic hyperglycemia.
Despite lifestyle changes and use of oral antidiabetic drugs,
reduced percentage of the target glycolated hemoglobin
(HbA1c) could not be obtained (2).
Insulin analogues have been developed to imitate the
body’s natural physiological secretion of insulin. Insulin
aspart, insulin glulisine, and insulin lispro are rapid-acting
insulin analogues. Insulin glargine and insulin detemir are
long-acting insulin analogues and are used for provision
of basal insulin levels (3,4). Intensive insulin therapy can
reduce the risk of developing microvascular complications,
or can delay the start of such complications by imitating
* Correspondence: ckaratoprak@hotmail.com
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baseline and postprandial insulin secretions. The most
common side effects of insulin therapy are hypoglycemia,
weight gain, insulin edema, allergy, antibody formation,
and lipodystrophy (5). Studies reported that weight
gain due to insulin was less with the use of analogue
insulins than with human insulins (6–9). Despite these
developments, weight gain due to insulin use continues to
be a problem for many patients and doctors.
We could find no study in the literature about the
effects of insulin analogues on weight gain in patients
who use them. In our study, we aimed to investigate the
effects of short-acting analogue insulins on weight, and to
demonstrate the differences between them.
2. Materials and methods
Our study included 118 patients who used insulin glargine
for 3–6 months with short-acting analogue insulins, i.e.
insulin aspart (ins asp; 38 patients), insulin lispro (ins lis;
28 patients), and insulin glulisine (ins glu; 52 patients).
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Our study included patients who have used only
intensive insulin therapy with metformin. Those who
took other oral antidiabetics, other insulin derivatives,
or different insulin combinations were excluded from the
study because of the adverse effects on patients’ weights.
Patients’ weights were recorded before and after 3 to 6
months of insulin use in order to determine the effects
of insulins on weight gain. Each of the 3 groups were
designed so that patients shared similar body mass index
(BMI), sex, age, insulin dose, age of diabetes onset, and
HbA1c levels. Patients were followed by the same dietician
and used similar diet programs. In addition, patients’ low
density lipoprotein cholesterol (LDL-C) and triglyceride
levels were examined. The study received ethics committee
approval from the Bezmialem Vakıf University Faculty of
Medicine.
HbA1c levels were measured by turbidimetric
inhibition immunoassays. Triglyceride concentrations
were measured by enzymatic assay (Boehringer
Mannheim, Manheim, Germany). LDL-C was calculated
with the Friedewald formula.
2.1. Statistical analysis
SPSS for Windows 13.0 was used for data analysis.
Besides descriptive statistics (mean, median, and standard
deviation), comparison of normally distributed parameters
used one-way ANOVA, the post hoc Tukey test, and paired
samples t-tests. For comparison of abnormally distributed
parameters, Kruskal–Wallis, Mann–Whitney U, and
Wilcoxon tests were used. The chi-square test was used
to compare proportional data. Two-sided P-values of less
than 0.05 were considered significant.

3. Results
This study consisted of 118 patients divided into 3 groups
depending on whether they had used insulin glargine/
ins asp (n = 38), insulin glargine/ins lis (n = 28), or
insulin glargine/ins glu (n = 52). The 3 groups showed no
statistically significant difference as to sex, age (P = 0.99),
BMI, diabetes mellitus onset age, insulin glargine and
short-acting insulin analogue doses, and baseline HbA1c
levels (P = 0.76, P = 0.13, P = 0.57, P = 0.12, P = 0.21, and
P = 0.18, respectively; Table 1).
Examination of weight changes in each of the 3 groups
after 3–6 months of using short-acting insulin analogues
showed that patients in the groups that used ins asp or
ins glu gained weight. For the latter (ins glu), the gain was
statistically significant (P = 0.008). Despite expectations,
patients who used ins lis experienced weight loss.
Comparison of weight changes between the ins lis and ins
glu groups was statistically significant (P = 0.03).
Patients who had used analogue insulin were classified
into 1 of 3 groups depending on whether they had lost
weight (usually in the group that had used ins lis, P = 0.01),
gained weight (mostly from the ins glu group), or had no
weight change. Statistical significance was found in those
who, in addition to insulin therapy, used metformin (1
pill of 1000 mg twice daily). Patients who used metformin
were more often in the patient group that used ins glu (P =
0.02; Tables 2 and 3; Figures 1 and 2).
Patients in 3 groups were measured before and after
a treatment period of 3 to 6 months with the following
results for each group (Table 4):
1. Cholesterol levels: no statistical difference (P = 0.6, P
= 0.4, P = 0.4, respectively).

Table 1. Comparison of age groups, BMI, and HbA1c.
Ins asp
(n = 38)
Mean ± SD

Ins lis
(n = 28)
Mean ± SD

Ins glu
(n = 52)
Mean ± SD

P

Age

51.5 ± 10

52.3 ± 9.8

50.5 ± 10

0.76

BMI (kg/m²)

31.4 ± 6.6

28.2 ± 7.6

31.1

0.13

Diabetes age (years)

14.9 ± 7.7

13.8 ± 6.7

12.9 ± 6.7

0.57

Glargine (U)

27.7 ± 8.8

27.9 ± 7.4

32.7 ± 12.7

0.12

Short-acting insulin (U)

38.8 ± 14.2

46.9 ± 15.2

39.4 ± 18.6

0.21

8.9 ± 1.8

9.0 ± 2.1

9.6 ± 1.8

0.18

HbA1c (%)

Ins asp: insulin glargine + insulin aspart, ins lis: insulin glargine + insulin lispro, ins glu: insulin glargine +
insulin glulisine, SD: standard deviation, BMI: body mass index, HbA1c: glycated hemoglobin, U: units.
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Table 2. Comparison of weight gain of the groups.
Ins asp
(n = 38)
Mean ± SD

Ins lis
(n = 28)
Mean ± SD

Pretreatment weight (kg)

³80.7 ± 15.2

£

Posttreatment weight (kg)

³80.8 ± 15.0

Weight change (g)

39 ± 27

P

Ins glu
(n = 52)
Mean ± SD

P

80.8 ± 13.9

0.4

76.3 ± 17.0

â

£

75.9 ± 16.8

â

81.8 ± 14.4

0.24

–428 ± 19*

1029 ± 27*

0.03

0.25

³0.93

0.008

£

â

Ins asp: insulin glargine + insulin aspart, ins lis: insulin glargine + insulin lispro, ins glu: insulin glargine +
insulin glulisine, SD: standard deviation.
*: Significant weight difference between ins lis and ins glu (P = 0.04).
3: P-value for ins asp group before and after treatment, £: P-value for ins lis group before and after treatment,
â: P-value for ins glu group before and after treatment.
Table 3. Comparison of weight gain and additional therapy of the groups.
Ins asp
(n = 38)

Ins lis
(n = 28)

Ins glu
(n = 52)

Increased weight, n (%)

17 (44.7)

6 (21.4)

32 (61.5)

No weight change, n (%)

9 (23.7)

8 (28.6)

9 (17.3)

Decreased weight, n (%)

12 (31.6)

14 (50)

11 (21.2)

Used metformin, n (%)

15 (39.5)

10 (35.7)

33 (63.5)

Did not use metformin, n (%)

23 (60.5)

18 (64.3)

19 (36.5)

P

0.01+

0.02*

Ins asp: insulin glargine + insulin aspart, ins lis: insulin glargine + insulin lispro, ins glu: insulin glargine +
insulin glulisine.
+: Weight changes were statistically significant in the ins lis and ins glu groups (P = 0.002).
*: Weight changes were statistically significant between the ins lis and ins glu groups (P = 0.03).
35
30

1500
1000

Count

25

Weight difference (g)

0
Ins asp
39

Ins lis
–428

Ins glu
1029

Figure 1. Weight changes according to groups: insulin glargine +
insulin aspart (ins asp), insulin glargine + insulin lispro (ins lis),
and insulin glargine + insulin glulisine (ins glu).
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Figure 2. The distribution of those who lost weight, whose weight
did not change, and whose weight increased, according to groups
as defined in caption to Figure 1.
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Table 4. The first and last measured LDL-C, triglycerides, and HbA1c levels.
Ins asp
(n = 38)
Mean ± SD

Ins lis
(n = 28)
Mean ± SD

116.6 ± 47.4

+

Ins glu
(n = 52)
Mean ± SD

P
0.6
0.4
€
0.4
*

LDL-C, first (mg/dL)

*

122.3 ± 31

€

116.6 ± 38

€

LDL-C, last (mg/dL)

*

112.9 ± 31

+

Triglycerides, first (mg/dL)

*

175.9 ± 10

+

Triglycerides, last (mg/dL)

*

197.2 ± 19

+

111.6 ± 38

+

106.7 ± 31
0.9
0.2
€
0.6
*

155.9 ± 10
177.3 ± 13

€

180 ± 17

+

184.1 ± 21

€

0.8
0.6
€
0.7
*

HbA1c, first (%)

*

HbA1c, last (%)

*

8.9 ± 1.8

+

9.0 ± 2.1

9.0 ± 1.8

+

8.9 ± 2.1

€

9.6 ± 1.8

+

9.5 ± 2

€

Ins asp: insulin glargine + insulin aspart, ins lis: insulin glargine + insulin lispro, ins glu: insulin glargine +
insulin glulisine, LDL-C, low-density lipoprotein cholesterol, HbA1c: glycated hemoglobin.
*: Shows P-value of before treatment and after treatment for LDL-C, triglycerides, and HbA1c of ins asp group.
+: Shows P-value of before treatment and after treatment for LDL-C, triglycerides, and HbA1c of ins lis group.
€: Shows P-value of before treatment and after treatment LDL cholesterol, triglycerides, and HbA1c of ins glu
group.

2. Triglyceride levels: no statistical difference (P = 0.9,
P = 0.2, P = 0.6, respectively).
3. HbA1c levels: no statistical difference (P = 0.8, P =
0.6, P = 0.7, respectively).
HbA1c levels measured at the beginning of treatment
were similar in all 3 groups with no statistical difference
among them (P = 0.18). After intensive treatment for 3 to
6 months, only 10.2% of the patients reached the targeted
HbA1c level (<7%). There was no significant difference
among the 3 groups who used insulin in achieving the
target HbA1c level (P = 0.37).
4. Discussion
Short-acting analogue insulins imitate physiological
insulin secretion but have the negative side effect of causing
weight gain. The aim of our study was to determine the
potential weight gain of short-acting analogue insulins
in patients who use them and to determine possible
differences between the analogue insulins. In addition,
we aimed to determine the effects of analogue insulins on
LDL-C and triglycerides. In order to reduce unintended
external effects that could alter the results, our study
included patients with similar demographic characteristics
and HbA1c levels. To determine the effect of short-acting
insulin analogues, our study included only patients who
had used insulin glargine as long-acting insulin.

Analysis of pre- to posttreatment weight change of
all 3 groups showed that the patients who used ins asp
and ins glu gained weight (up to 6 kg), whereas patients
who used ins lis lost weight. This result was statistically
significant. Patients who had used ins glu gained a
statistically significant amount of weight. For this reason,
we divided patients into 3 groups: those who lost weight,
those who gained weight, and those whose weight did
not change. Even in this situation, the results remained
unchanged and statistically significant. The majority of the
weight loss patients were in the group that had used ins
lis. The majority of the weight gain patients were in the
group that had used ins glu. Evaluating other drugs that
could possibly affect the results, we found that this was
only the case among metformin users, most of whom were
in the group that had used ins glu. This was statistically
significant. Since metformin is an oral antidiabetic that
may help in weight loss, one may reasonably assume that
ins glu used alone might lead to weight gain.
We found no studies related to any effect on weight
gain of our 3 short-acting insulin analogues. Some studies
investigated weight gain of users of other insulin groups,
such as neutral protamine Hagedorn (NPH) insulin,
insulin detemir, and insulin glargine (6–10). Temizel et al.,
comparing analogue insulin mixtures at 6 and 12 months
in their study, found a 1.41 ± 2.7 kg and 2.08 ± 3.7 kg weight
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gain in patients using ins lis and a 1.5 ± 3.0 kg and 2.29 ±
3.8 kg weight gain in patients using ins asp, respectively,
but these results did not have statistical significance (11).
Similarly, in our study, we found no difference between ins
asp and ins lis, except that ins lis had less effect on weight
gain. Fritsche et al. compared insulin glargine and ins glu
(basal-bolus therapy) and insulin premix (twice daily) and
found that by week 52, patients using basal-bolus therapy
gained 3.6 kg and patients using insulin premix gained
4.5 kg. They also found that HbA1c levels of the patients
using basal-bolus therapy decreased 1.31%, and HbA1c
levels of the patients using insulin premix decreased 0.8%
(P = 0.0001) (12). Even though the duration of our study
was shorter, their insulin glargine and ins glu results are
relatively similar to ours. In that study, although they used
intensive treatment for 52 weeks, patients did not achieve
target HbA1c levels.
In our study, when we considered the causes for these
differences, we thought that short-acting insulin analogues
had similar effects and features, but essentially they are
different molecules. Therefore, although the starting time

of effect, peak time, and duration of the action of ins
asp and ins lis are similar, ins glu has a shorter duration
of action and so its peak time is faster (13). Periods of
hypoglycemia lengthen as a result of more rapidly declining
plasma glucose levels. Depending on this rapid peak and
more short-term effect, the feeling of hunger increases and
patients eat more, which leads to adverse effects on weight.
In addition, although patients received intensive insulin
therapy, patients could not achieve the expected HbA1c
levels, but this was not a factor that could have affected
weight gain because HbA1c levels were similar in all 3
groups.
In conclusion, our study showed that patients who
used short-acting insulin analogues gained a little weight,
patients who used ins glu gained the most weight, and
patients who used ins lis lost weight. The effects of shortacting insulin analogues on LDL-C and triglyceride levels
were neutral. As a result, when selecting intensive insulin
therapy for a patient, weight gain should be taken into
account, and treatment options should be determined by
taking into consideration the patient’s condition.
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